Litigation Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

« Back to Dashboard

Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Docket	1:17-cv-00663-JFB-SRF	Date Filed	2017-06-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	9,517,219
Link to Docket	External link to docket

Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-01	137		would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least	External link to document

Almirall LLC v. Taro Pharmaceutical Industries Ltd.: Litigation Summary and Patent Analysis

Last updated: October 6, 2026

Almirall LLC v. Taro Pharmaceutical Industries Ltd., No. 1:17-cv-00663-JFB-SRF, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Taro’s proposed generic version of Almirall’s ACZONE topical dapsone product. Almirall sued after receiving Taro’s Paragraph IV certification. The case was assigned to Judge Joseph F. Bataillon and Magistrate Judge Sherry R. Fallon. The litigation ended without a publicly reported merits judgment, and the commercial terms of the parties’ resolution were not disclosed in the public docket. [1]

What drug and product were at issue in Almirall v. Taro?

The dispute concerned topical dapsone gel, marketed by Almirall under the ACZONE brand for acne vulgaris.

ACZONE product profile

Item	Detail
Brand	ACZONE
Active ingredient	Dapsone
Dosage form	Topical gel
Relevant strength	7.5% gel
Reference sponsor	Almirall LLC
Regulatory pathway	ANDA patent litigation under Hatch-Waxman
Proposed challenger	Taro Pharmaceutical Industries Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00663-JFB-SRF
Filing year	2017

Dapsone is an antimicrobial and anti-inflammatory compound used in topical acne treatment. The commercial dispute centered on whether Taro could obtain FDA approval and market a generic dapsone gel before expiration of Almirall’s listed patent rights.

The case was part of a broader wave of generic challenges directed at ACZONE. Other generic-drug companies also pursued approval for topical dapsone products, creating a market-entry risk for Almirall independent of Taro’s specific case.

What patents protected ACZONE in the Taro litigation?

Almirall’s ACZONE patent estate included formulation and topical-composition patents directed to dapsone gel products. Public patent records and Orange Book materials identify patents associated with ACZONE, including patents in the 8 million and 9 million series. The specific patent claims asserted against Taro must be read from the complaint, infringement contentions, and later docket filings rather than inferred solely from the Orange Book listing.

Patent categories implicated by the dispute

The asserted rights generally fell into the following categories:

1. Topical dapsone compositions.
2. Gel formulations containing dapsone.
3. Formulation characteristics intended to improve product performance or tolerability.
4. Method-of-treatment claims covering use of topical dapsone for acne.

A Hatch-Waxman suit does not require an innovator to prove that every patent covering the branded product will survive. The relevant question is whether at least one asserted patent is valid, enforceable, and infringed by the proposed ANDA product.

Patent estate considerations

The strength of Almirall’s position depended on the claim scope of the asserted formulation patents. Composition claims can provide a direct infringement theory if the generic product contains the claimed ingredients and concentrations. Method-of-use claims can be more difficult to enforce against a generic applicant because the approved labeling, not merely the formulation, becomes important.

For a topical product, formulation patents may create a stronger barrier than broad method claims when the generic applicant must use substantially the same active ingredient and dosage form to obtain approval. The strength of that barrier still depends on claim construction, prior art, prosecution history, and whether the generic formulation falls within the asserted limitations.

When did Almirall file the case against Taro?

The case was filed in 2017 in the District of Delaware after Taro notified Almirall that it had submitted an ANDA containing a Paragraph IV certification against ACZONE-related patents. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Almirall’s complaint triggered the 30-month stay under the Hatch-Waxman framework, assuming the statutory requirements were satisfied. During the stay, FDA approval of the ANDA could be delayed even if the FDA had completed its substantive review. The stay did not itself determine patent validity or infringement.

Litigation timeline

Date or period	Event
2017	Taro submitted an ANDA challenge and provided Paragraph IV notice
2017	Almirall filed suit in the District of Delaware
2017-2018	Pleadings, discovery, and pretrial activity proceeded
2018	The case ended through a negotiated resolution or stipulated termination
After termination	No publicly reported trial judgment against Taro appears in the case docket

The docket designation "JFB-SRF" identifies Judge Joseph F. Bataillon and Magistrate Judge Sherry R. Fallon. The case was not assigned to a specialized patent judge, although Delaware applies established local patent procedures to such disputes.

Was this a Paragraph IV patent challenge?

Yes. The case was a Hatch-Waxman action arising from Taro’s ANDA certification. The litigation therefore involved the standard generic-entry questions:

• Whether Taro’s proposed product infringed the asserted ACZONE patents.
• Whether those patents were invalid in view of prior art.
• Whether any asserted claims were unenforceable.
• Whether the 30-month FDA approval stay would expire before a settlement-authorized launch date.
• Whether Taro could enter at risk if the case were dismissed without a final merits ruling.

Paragraph IV litigation creates a statutory pathway for generic applicants to challenge listed patents before commercial launch. It also permits the first qualifying Paragraph IV filer to seek 180-day exclusivity in some circumstances. The public record for this case does not establish that Taro obtained first-filer status or 180-day exclusivity.

What was the outcome of Almirall v. Taro?

The litigation did not produce a publicly reported finding that the asserted patents were invalid or infringed. The case terminated before a merits decision that would establish a binding judicial outcome on those issues.

The available public record indicates that the parties resolved the dispute and that the action was dismissed or terminated pursuant to their agreement. Public docket termination does not mean that the patents were held valid. It also does not mean that Taro was cleared to launch immediately.

What the outcome does and does not establish

Issue	Publicly established result
Patent validity	No reported final merits determination
Patent infringement	No reported final merits determination
FDA approval	Not established by the litigation docket alone
Taro launch date	Not established by a public merits judgment
Settlement terms	Commercial terms were not publicly detailed
Enforceability ruling	No reported final ruling
Precedential value	Limited, because the case ended without a substantive opinion

A settlement usually reflects a negotiated allocation of launch timing and litigation risk. It does not provide the market with the same information as a trial verdict or a Federal Circuit decision.

Did the parties sign a settlement agreement?

The case ended through a resolution rather than a publicly reported trial. The public docket does not disclose the full commercial terms of any settlement agreement.

In pharmaceutical patent settlements, the principal term is often an agreed generic-entry date. Other provisions can include:

• A license to the branded company’s patent estate.
• A covenant not to sue on specified patents.
• Restrictions on the generic product’s labeling.
• Entry rights triggered by another generic entrant.
• Acceleration provisions following patent invalidation.
• A supply or authorized-generic arrangement.
• Mutual releases.

Because those terms were not publicly reported in the case record, Taro’s exact permitted launch date, if any, cannot be treated as established from the dismissal alone.

What was the Orange Book status of ACZONE?

ACZONE was listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Orange Book listings identify patents that the NDA holder or sponsor represents as covering the drug, its formulation, or an approved method of use. [2]

An Orange Book listing does not mean that a patent has been judicially validated. It gives the generic applicant a basis to submit a Paragraph IV certification and gives the NDA holder a basis to bring an infringement action under 35 U.S.C. § 271(e)(2).

Orange Book implications

The ACZONE listings were commercially important because they:

• Defined the patent certifications that Taro had to address.
• Created the statutory basis for Almirall’s lawsuit.
• Potentially delayed FDA approval through the 30-month stay.
• Allowed Almirall to negotiate market protection without relying on post-launch damages alone.
• Created separate risk for later generic applicants that might certify against the same patents.

The Orange Book does not list every patent that could be asserted against a generic product. It generally excludes patents that do not meet FDA listing standards, including some manufacturing, process, and certain packaging rights. A generic applicant can therefore face non-Orange Book patent risk after approval.

How strong was Almirall’s patent estate?

Almirall’s ACZONE estate had meaningful commercial value because the product was a topical formulation rather than a simple oral tablet. Topical formulations can create additional technical barriers involving vehicle composition, drug distribution, release characteristics, stability, skin tolerability, and manufacturing controls.

The estate’s strength was moderated by several factors:

Formulation patent risk

Formulation patents are strongest when the claims require technical features that a generic applicant cannot avoid while maintaining equivalent performance. They are weaker when the claims use broad ingredient ranges, cover routine excipients, or depend on limitations disclosed in earlier topical products.

Method-of-use risk

Method patents covering acne treatment can be narrower than composition patents. Their practical value depends on the approved label and on whether the generic product’s proposed labeling induces the claimed use.

Prior-art risk

Dapsone was an old active pharmaceutical ingredient. The principal validity question was therefore less likely to concern whether dapsone itself was new and more likely to concern the claimed topical formulation, concentration, vehicle, delivery profile, or treatment method.

Patent-term timing

The commercial value of the estate depended on the remaining patent term at the time of settlement. A settlement reached several years before patent expiry can preserve substantial value for the branded sponsor while giving the generic applicant a defined future entry opportunity.

Did Taro launch a generic ACZONE product?

The case docket does not establish an immediate Taro launch. A patent case dismissal, standing alone, does not prove that a generic product entered the market.

FDA approval and commercial launch are separate events. Taro would have needed an approved ANDA, resolution of any remaining patent or regulatory barriers, commercial manufacturing capacity, and a launch strategy. A company may also hold an approved ANDA without immediately selling the product.

The market-entry analysis should therefore distinguish among:

1. ANDA submission.
2. FDA approval.
3. Settlement-authorized launch.
4. Actual commercial distribution.
5. Prescription substitution and market-share capture.

What generic-entry risks did Almirall face?

Almirall faced several distinct risks from Taro and other generic applicants.

At-risk launch

If the litigation ended without an injunction and the statutory stay expired, Taro could potentially launch before all patent disputes were fully resolved. An at-risk launch would expose Taro to damages and possible injunctive relief if Almirall later prevailed.

Multiple generic applicants

A settlement with one applicant would not necessarily prevent other ANDA filers from challenging the same patents. Each applicant could create separate litigation and launch pressure.

Formulation substitution

Topical products can experience slower generic substitution than oral solid dosage forms because physicians and patients may perceive differences in vehicle feel, drying, irritation, or application characteristics. That can reduce, but not eliminate, the commercial impact of generic entry.

Patent-expiration compression

If the principal ACZONE patents were nearing expiry, a settlement could shift the dispute from an immediate injunction question to a negotiated launch-date question. The shorter the remaining exclusivity period, the less economic value a full trial may have relative to settlement.

How does this case compare with other ACZONE generic litigation?

Almirall v. Taro was one proceeding within a larger competitive challenge to ACZONE. The existence of multiple defendants changes the bargaining position of both sides.

Factor	Effect on Almirall	Effect on generic applicants
Multiple Paragraph IV filers	Increases cumulative erosion risk	Creates opportunities for earlier entry or competitive settlement
Formulation patents	May support infringement claims	Can increase development and litigation costs
Older active ingredient	Limits protection from active-ingredient novelty	Shifts dispute toward formulation and method claims
Topical dosage form	May slow substitution	Creates manufacturing and equivalence challenges
Settlement with one defendant	Provides certainty against that defendant	May preserve a negotiated launch path
No merits ruling	Leaves patent strength unresolved	Avoids adverse precedent for later challengers

The absence of a merits judgment means the case provides limited guidance on how a court would construe or evaluate the asserted claims. Later ACZONE litigation, FDA decisions, patent reexaminations, or appellate rulings would have greater value for assessing the estate.

What is the business significance of the case?

The principal commercial issue was the timing and certainty of generic entry for ACZONE 7.5% gel. The case likely affected revenue exposure through three channels:

1. The duration of Almirall’s effective market exclusivity.
2. The number and timing of generic entrants.
3. The degree of price erosion after substitution became available.

A single generic entrant can produce meaningful price pressure, but topical products may show a different erosion curve from oral drugs. Manufacturing complexity, prescriber preference, payer policy, and pharmacy substitution rules all affect uptake.

The case did not create a published judicial test for ACZONE patents. Its practical value was transactional: it converted an uncertain patent dispute into a negotiated resolution and avoided the cost and risk of a Delaware trial.

Key Takeaways

• Almirall sued Taro in 2017 under Hatch-Waxman after Taro filed a Paragraph IV challenge involving generic topical dapsone gel.
• The product at issue was ACZONE, a dapsone gel used to treat acne vulgaris.
• The dispute focused on formulation and related patent rights rather than novelty of the dapsone active ingredient.
• The case ended without a publicly reported trial verdict on validity, infringement, or enforceability.
• The public record does not disclose the parties’ full settlement terms or establish an immediate Taro launch.
• Orange Book listings created the statutory foundation for the lawsuit and potentially triggered the 30-month FDA approval stay.
• The litigation left Almirall’s patent strength unresolved for later challengers.
• Generic-entry risk remained dependent on other ANDA filers, patent expiration, FDA approval, and commercial launch decisions.

FAQs About Almirall LLC v. Taro Pharmaceutical Industries Ltd.

What was the case number for the ACZONE patent litigation?

The case number was 1:17-cv-00663-JFB-SRF in the U.S. District Court for the District of Delaware.

Did Taro win the ACZONE patent case?

No merits win by Taro was publicly reported. The case ended without a published judgment holding the asserted patents invalid or not infringed.

Was ACZONE a biologic subject to biosimilar litigation?

No. ACZONE is a small-molecule topical dapsone product. The relevant pathway was an ANDA under Hatch-Waxman, not a biosimilar application under the Biologics Price Competition and Innovation Act.

Did the case establish that Almirall’s ACZONE patents were valid?

No. A settlement or dismissal does not judicially validate the patents. No final merits ruling in the case established validity.

Could another generic company challenge ACZONE after the Taro settlement?

Yes. A settlement with Taro would not automatically eliminate challenges by other ANDA applicants. Each applicant could present separate invalidity, noninfringement, or unenforceability arguments.

References

1. U.S. District Court for the District of Delaware. (2017). Almirall LLC v. Taro Pharmaceutical Industries Ltd., No. 1:17-cv-00663-JFB-SRF. Court docket and filings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA, Center for Drug Evaluation and Research.

3. U.S. Code. (2024). 21 U.S.C. § 355(j), abbreviated applications and patent certifications.

4. U.S. Code. (2024). 35 U.S.C. § 271(e)(2), infringement relating to drug approval applications.